A Human Hepatocyte-Bearing Mouse: An Animal Model to Predict Drug Metabolism and Effectiveness in Humans by Yoshizato, Katsutoshi & Tateno, Chise
Hindawi Publishing Corporation
PPAR Research
Volume 2009, Article ID 476217, 11 pages
doi:10.1155/2009/476217
Review Article
AHuman Hepatocyte-Bearing Mouse:An AnimalModelto
PredictDrug Metabolism and Effectivenessin Humans
Katsutoshi Yoshizato1,2 andChise Tateno1
1PhoenixBio, Kagamiyama, 3-4-1 Kagamiya, Higashihiroshima 739-0046, Japan
2Osaka City University Gradate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
Correspondence should be addressed to Katsutoshi Yoshizato, katsutoshi.yoshizato@phoenixbio.co.jp
Received 9 April 2009; Accepted 13 July 2009
Recommended by James P. Hardwick
Preclinical studies to predict the eﬃcacy and safety of drugs have conventionally been conducted almost exclusively in mice and
rats as rodents, despite the diﬀerences in drug metabolism between humans and rodents. Furthermore, human (h) viruses such as
hepatitis viruses donot infect the rodentliver. A mouse bearing a liver in which thehepatocytes have been largely repopulated with
h-hepatocytes would overcome some of these disadvantages. We have established a practical, eﬃcient, and large-scale production
system for such mice. Accumulated evidence has demonstrated that these hepatocyte-humanized mice are a useful and reliable
animal model, exhibiting h-type responses in a series of in vivo drug processing (adsorption, distribution, metabolism, excretion)
experiments and in the infection and propagation of hepatic viruses. In this review, we present the current status of studies on
chimeric mice and describe their usefulness in the study of peroxisome proliferator-activated receptors.
Copyright © 2009 K. Yoshizato and C. Tateno. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The human (h)-body consists of approximately 30 organs,
each of which fulﬁlls a speciﬁc function, autonomously yet
cooperatively with other organs, to maintain life. The liver
is essential to (h)-life, as it participates in the control of
energy balance and plays central roles in the metabolism
and excretion of ingested food and chemicals. Knowledge
of the mechanisms underlying the functions of the h-liver
is important for understanding the biology of the liver as
well as for clinically treating liver-damaged patients and for
studying drug pharmacology in humans. The ideal approach
toelucidating the mechanisms responsible forliverfunctions
wouldbetoperformexperimentsusingtheh-liverinsitu,but
of course this approach is not realistic. Therefore, scientists
have taken two other approaches: in vitro examination of
samples isolated from the h-body (in vitro/human), and in
vivo examinations using animals (in vivo/animal). Although
these two approaches, separately and together, have revealed
much about the mechanisms governing the functions and
morphology of the h-liver, they are inherently limited by
the complexity of the biological phenomena and the species
diﬀerencesinhomologousmechanismsbetweenanimalsand
humans.
The complexity of a biological phenomenon results from
the required mutual interactions of multiple diﬀerent com-
ponents.Thespeciﬁccellsthatrepresentanorgan’sfunctions
are collectively termed parenchymal cells. For example, the
parenchymal cells of the liver are hepatocyte, because they
perform liver-speciﬁc functions such as the synthesis and
secretion of serum proteins and the synthesis of metabolism-
related enzymes, including liver-speciﬁc cytochrome P450
(CYP450) proteins. However, hepatocytes by themselves are
unable to fulﬁll liver functions and require the cooperation
of nonparenchymal liver cells such as hepatic blood vessels,
bile duct biliary cells, Kupﬀer cells, and stellate cells in the
space of Disse, located between the hepatic plate and the
sinusoids [1]. The portal vein is the major import route
for nutrients to the liver, via the hepatic sinusoids, from
the small and most of the large intestine, the spleen, and
the pancreas. Nutrients and oxygen in the sinusoids and
secretory proteins in the hepatocytes are exchanged through
thespaceofDisse.Stellatecells,themajorcelltypeproducing
extracellular matrix components in the liver, are located2 PPAR Research
adjacent to the hepatocytes and the sinusoidal endothelial
cells [2]. Hepatocytes, endothelial cells, and stellate cells
represent 65, 21, and 6%, respectively, of the h-liver and are
the main cells responsible for liver functions [1].
Interactive cooperation among diﬀerent cells types is
a principal way in which a multicellular entity is able to
function as a living system. It is also a major source of the
limitations in in vitro/human studies. To date, no studies
have successfully reconstituted an in vitro/h-liver system that
perfectly mimics the events that occur in the h-liver in vivo.
This limitation has prompted a search for an in vivo/animal
experimental system appropriate for providing animal data
thatcanbeextrapolatedtohumans.However,animalmodels
must address the challenge of species diﬀerences in the genes
and proteins associated with a biological phenomenon.
The liver processes nutrients from the gut and intestines
into proteins, lipids, and carbohydrates. It also serves an
endocrine function by secreting albumin (Alb), most coagu-
lation factors, several plasma carrier proteins, and lipids into
the blood. In addition, the liver synthesizes bile and secretes
it into the digestive tract. The elaborate histological structure
of the liver optimizes these functions [3]. Hepatocytes are
well organized in an aggregated association (the hepatic
epithelium) of polarized hepatocytes, creating small apical
domains that line the channels between cells (canaliculi).
These channels connect to the bile ducts, which drain
into the intestine. The basal sides of the hepatocytes are
juxtaposed to the fenestrated endothelium of the sinusoids,
into which blood ﬂows from the arterial and intestinal portal
circulations before emptying into the venous circulation [4].
h-Hepatocytes are indispensable for an in vitro/human
liver study. Nevertheless, the preparation of h-hepatocytes
in suﬃcient numbers for experimental purposes is diﬃcult
because the source is very limited and because h-hepatocytes
do not abundantly proliferate and grow in vitro. This led
us to create a mouse (m) bearing a liver composed almost
entirely of h-hepatocytes. This approach may simultaneously
abolish the limitations of both in vitro/human and in
vivo/animal studies. With this m-model, a small number of
available h-hepatocytes could abundantly proliferate in the
m-liv erforuseininvitro/humanstudies.Furthermore,these
mice would provide a superior new type of model animal
for in vivo/animal studies, because fewer species diﬀerences
would exist with respect to liver functions.
We have called this type of mouse a “liver-humanized
mouse,” or simply a chimeric mouse, although the correct
name should be “hepatocyte-humanized mouse.” The idea
of a h-liver chimeric mouse was originally described by
Brinster’s group in 1995 [5] and was actualized by the two
groups in 2001 to study h-hepatitis B virus (h-HBVs) [6]
and h-HCV infections [7], and later, in 2004, by us to
study the in vivo growth capacity of h-hepatocytes and the
gene and protein expression of CYPs [8]. One year later,
a detailed morphological study of a chimeric m-liver was
reported by Meuleman et al. [9]. Kneteman and Mercer
brieﬂy reviewed the current chimeric mouse studies [10]. In
thisarticle,wereviewthestudiesonchimericmice,including
their short historical background, usefulness in testing h-
type metabolism of clinically usable drugs, and potential
use in examining h-type peroxisome proliferator-activated
receptors (PPARs), especially PPARα, which plays key roles
in the metabolism of xenobiotics in an animal species-
dependent manner. We demonstrate that h-hepatocytes
propagated in a chimeric m-liver and then isolated can serve
as normal h-hepatocytes for an in vitro/human model [11].
2.A Mouse BearingTransplantedHomogenic
and Xenogenic Hepatocytes
To study neonatal bleeding disorders, transgenic mice
(TgAlb-uPA) carrying a tandem array of about four Albu-
minpromoter/enhancer-drivenurokinase-typeplasminogen
activator (uPA) genes were created [12]. Their hepatocytes
over-produce murine urokinase, and the liver becomes
severely hypoﬁbrinogenemic, which accelerates hepatocyte
death. Sandgren et al. [13] developed a model of liver
regeneration in TgAlb-uPA mice, in which a chronic stimulus
for liver growth was generated due to a functional liver
deﬁcit. When a hepatocyte stochastically deleted the dele-
terious transgene, the hepatocytes of mice hemizygous for
the transgene started to replicate and selectively expanded to
regain the original size of the liver. Transgene expression in
the replicating hepatocytes was abolished because of a DNA
rearrangementthataﬀectedthetransgenetandemarray.This
permitted the individuals to survive beyond birth, and the
plasma uPA concentrations gradually returned to normal by
2 months of age. The transgene-deﬁcient cells formed clonal
colonies called hepatic nodules. These nodules expanded
and replaced the surrounding transgene-active cells, which
could not replicate because of cellular damage. Eventually,
the transgene-deﬁcient cells replaced the entire liver. This
study demonstrates the usefulness of the TgAlb-uPA mouse for
examiningthereplicativecapacityofnotonlym-hepatocytes,
which was successfully done by transplanting hepatocytes
isolated from adult mice into the transgenic mice [14], but
also hepatocytes of mammals that acquire immunotolerance
as follows.
Rhim et al. [5] introduced the Alb-uPA transgene into
immunotolerant nu/nu mice by mating TgAlb-uPA mice
with Swiss athymic nude mice, generating immunotolerant
TgAlb-uPA mice (TgAlb-uPA/NUDE mice). Rat (r)l i v e rc e l l s
were transplanted into the livers of TgAlb-uPA
+/+/NUDE mice
homozygous for the transgene. The host livers that had not
been transplanted with r-liver cells were completely pale
(white).Incontrast,thosewithr-livercellshadwhiteregions,
representingtheareacomposedonlyoftransgene-expressing
host m-cells, and red regions, representing the area com-
posed of transgene-deleted host m-cells, repopulated r-cells,
or both. Immunohistochemical analysis with antibodies
against r-hepatocytes conﬁrmed that the red region was
composed primarily of r-hepatocytes. The completely regen-
erated transgenic m-livers resemble normal m-livers in color,
shape, and size. Southern blot analysis demonstrated that
up to 56% of the DNA was of rat origin, which agreed well
with the parenchymal cell occupancy rate in the liver. These
ﬁndings strongly support the idea that the host liver was
chimeric, with r-parenchyma and m-nonparenchymal cells,PPAR Research 3
which included vessels, bile ducts, and associated connective
tissues. The ratio of the liver weight to the body weight was
6.8%,whichwassimilartothatofthenon-transgeniccontrol
mice (5.8%), indicating that the rat-mouse (r/m) chimeric
livers were able to normally terminate growth. The successful
generation of a healthy mouse with a chimeric liver indicates
that r-parenchymal and m-nonparenchymal cells were able
to communicate with each other to reconstitute a functional
liver, despite the species diﬀerence.
Hepatocytes initiate and terminate proliferation under
the inﬂuence of nonparenchymal cells [1]. Thus, the normal
progression and termination of r/m-chimeric liver regener-
ation implies that r-hepatocytes produce surface proteins
thatinteractcorrectlywithsolublem-factors,m-extracellular
matrix, and m-surface proteins on m-nonparenchymal cells.
The successful replacement of TgAlb-uPA
+/+/NUDEm-livers
with r-hepatocytes raised the exciting possibility that m-
livers could also be reconstituted with h-hepatocytes [5].
3. Repopulation of h-Hepatocytesin m-Liver
In two previous studies to generate a mouse with a h-
hepatocyte-mouse (h/m)c h i m e r i cl i v e r ,R u g - 2 - k n o c k o u t
mice [6] and severe combined immunodeﬁcient (SCID)
mice [7] were used as immunodeﬁcient mating partners
for uPA transgenic mice. We mated SCID mice (miceSCID)
with TgAlb-uPA
+/+ mice to yield liver-injured SCID mice
(miceAlb-uPA/SCID)[ 8]. Normal h-hepatocytes, ∼106 viable
cells per mouse, were transplanted into the livers of these
mice at 20–30 days after birth. The h-hepatocytes engrafted
theliveratratesashighas96%andprogressivelyrepopulated
it. The repopulation after h-hepatocyte transplantation was
easily monitored by the increase in the h-Alb concentration
in the host blood, and the expansion of h-hepatocyte
colonies was visualized by immunohistological staining of
liver sections with h-speciﬁc anti-cytokeratin (CK) 8/18
antibodies. The ratio of the number of engrafted h-
hepatocytes to total hepatocytes (m-a n dh-hepatocytes) in
the host liver, which is the replacement index (RI), was
determined by calculating the ratio of the area occupied by
hCK8/18-positive hepatocytes to the entire area examined in
immunohistochemicalsectionsofsevenlobes.Itwasdemon-
stratedthatsustainedengraftmentofh-hepatocytesoccursin
homozygous Alb-uPA transgenic (Tg
+/+
Alb-uPA) mice, but not in
hemizygous transgenic (Tg
+/−
Alb-uPA)m i c e .T h eh-hepatocytes
started to proliferate around 7 days after transplantation.
Their colonies gradually became larger and were almost
conﬂuent at around 70 days, when the RI was as high as
96%. Immunohistological staining of liver sections for type
IVcollagen,laminin,stabilin(aliverendothelialcellmarker),
BM8 (a Kupﬀer cell marker), and desmin (a hepatic stellate
cell marker) demonstrated the chimeric nature of the liver
(Figure 1). The interactions between hepatocytes and stellate
cellsarecriticalforphysiologicalandpathologicalconditions
of the liver [15]. Close and seemingly normal associations
of h-hepatocytes with m-stellate cells were immunohistolog-
ically visualized by staining with speciﬁc antibodies against
h-CK8/18 (h-hepatocytes) and m-desmin (m-stellate cells)
(Figure 2). These results clearly show that the chimeric m-
livers with a high RI consisted of parenchymal cells (mostly
h-cells with a low percentage of m-cells),m-nonparenchymal
cells, and m-ECMs, in agreement with a previous study [9].
There was good correlation between the RI and the mRNA
expression levels of housekeeping genes such as h-Alb and
h-transferrin, supporting the notion that transplanted h-
hepatocytes are functional [16]. In our experience, mice
with >6mg/mL h-Alb in the blood had an RI >70%. Our
histological studies illustrated that the h-hepatocytes were
well organized and surrounded by m-nonparenchymal cells,
andtheyreconstitutedthenormaltissuesspeciﬁctoanormal
functional liver (described in Section 1), despite the large
species diﬀerence between humans and mice.
We chose robustly growing young mice as hosts. These
mice were able to not only survive but also grow, although
relatively slowly, and increase their body weight by >50%
of their original weight, during the replacement of host
m-hepatocytes with h-counterparts. These simple animal
experiments made us realize that m-cells and h-hepatocytes
were able to mutually communicate to maintain life: m-
cells supported the proliferation of h-hepatocytes, and h-
hepatocytes supported the growth of the young mouse. The
host liver of a mouseAlb-uPA/SCID is congenitally damaged
owing to uPA overproduction, low blood levels of Alb, and
signiﬁcantly high levels of alanine aminotransferase (ALT).
Repopulation of the h-hepatocytes in the liver increased the
blood Alb concentration and decreased the ALT level, indi-
cating that h-hepatocytes contributed to the improvement
of m-liver function [8]. Based on these considerations and
ﬁndings, we expect that a m-liver made of h-hepatocytes
would function as an apparently normal liver, metabolizing
and detoxifying endogenous and exogenous biomolecules.
4. Expression Proﬁles of h-Cytchrome P450s in
Relation to Phase 1 MetabolicEnzymes
Biochemical treatment of foreign substances (xenobiotics)
that have been absorbed into the body is one of the major
tasks of the liver. In hepatocytes, xenobiotics are pro-
cessed to more stable and hydrophilic derivatives by groups
of enzymes, collectively called xenobiotic-metabolizing
enzymes (XMEs), via two phases: phase 1, which is accom-
plished by oxidative enzyme, and phase 2, performed by
conjugating enzymes [17]. Ingested drugs, toxicants, and
chemical carcinogens are metabolized in phase I by CYP and
the ﬂavin-containing monooxygenase superfamily. Notably,
CYP is the key enzyme in the elimination of clinical drugs.
Humans and rodents respond diﬀerently to xenobiotics,
and this is explained in part by species diﬀerences in CYP
subfamilies. These species diﬀerences raise serious issues in
researchforclinicallyusablemedicines,becausetheresultsof
xenobiotic metabolism studies with mice and rats, which are
the most commonly used experimental models for pharma-
cological and toxicological studies, cannot be extrapolated
to humans. Thus, information about the expression of
CYP families and subfamilies should be valuable from two
viewpoints. First, the expression in h/m-chimeric mice of4 PPAR Research
Type IV collagen
(a)
Laminin
(b)
Stabillin II
(c)
BM8
(d)
Figure 1: The histological harmonization of h-hepatocytes with m-nonparenchymal cells. uPA/SCID mice were transplanted with h-
hepatocytes and allowed to grow until the repopulation of the liver was complete. Then, liver sections were prepared from the h-hepatocyte-
chimeric mice. Sections were immunostained with m-speciﬁc antibodies for type IV collagen (a); laminin (b); stabillin (c), a marker of liver
endothelial cells (a gift from Dr. A. Miyajima, Tokyo University); and BM8 (d), a marker of Kupﬀer cells. The immunosignals are brown.
The arrows in (c) and (d) point to typical immunopositive cells. Bar, 100μm.
a CYP subtype that is found in h-hepatocytes, but not in
mice, would be a good indication that the h-hepatocytes are
biochemically functional in the m-iver. Second, the h-CYP-
expressing chimeric mouse is a useful experimental model
for studying h-type metabolic responses to xenobiotics,
including clinically valuable drugs. Of note, CYP3A4 is the
most abundantly expressed CYP in h-liver and metabolizes
>60% of all therapeutic drugs; collectively, CYP2D6 and
CYP3A4 metabolize >70% of the drugs on the market [17].
Species diﬀerences in the CYP2C subfamily are well
known and have been characterized intensively [18, 19]. The
h-liver contains four CYP2C isoforms, CYP2C8, CYP2C9,
CYP2C18, and CYP2C19, all of which are absent from mice
and rats. Western blot analyses using h-speciﬁc antibodies
against CYP2C9 revealed positive signals with hepatocytic
microsomal fractions from h/m-chimeric mice with an RI
>34% and from the donor, but not with hepatocytic micro-
somalfractionsfromchimericmicewithanRI<28%orfrom
mice that had not been transplanted with h-hepatocytes.
CYP2C9 catalyzes the 4 -hydroxylation of diclofenac, and
the microsomal fractions from the chimeric mice showed
diclofenac 4 -hydroxylation activity that depended on the
RI of the mouse, strongly suggesting that the h-hepatocytes
in chimeric livers retain h-type pharmacological activity
toward drugs. One of the clearest and best-deﬁned examples
of a diﬀerence in a CYP between mice and humans is
CYP2D6 [20, 21], which is involved in the metabolism of a
large number of clinically used drugs [22, 23]. In humans,
CYP2D6 is the only active member of the CYP2D subfamily,
whereas rats and mice do not express a protein with the
enzyme activity of h-CYP2D6, although they do have at least
ﬁve other CYP2D genes [20, 24]. The enzymatic activity
of h-CYP2D6 in the chimeric mouse was demonstrated by
orally administering debrisoquin, a h-CYP2D6 substrate, to
the mice and subsequently detecting 4 -hydroxydebrisoquin,
a major debrisoquin metabolite produced by h-CYP2D6,
in the blood of the mice. Pretreatment of the mice with
quinidine, a typical h-CYP2D6 inhibitor, decreased the
level of the metabolite. Thus, a CYP enzymatic activity in
the chimeric mice was speciﬁcally induced by a CYP2D6-
metabolized drug and speciﬁcally suppressed by a CYP2D6
inhibitor [25].
Among the known CYP families, four families (CYP1–
4) play primary roles in XMEs. We compared the mRNA and
proteinexpressionproﬁlesofsixh-CYPs,CYP1A1,1A2,2C9,
2C19, 2D6, and 3A4, in the chimeric m-liver with those in
the donor liver [8]. Total RNA was prepared from the livers
of chimeric mice with diﬀerent RIs and of donors, and the
mRNA for the six h-CYPs was ampliﬁed in a quantitative
reverse-transcriptase polymerase chain reaction (qRT-PCR).PPAR Research 5
h-hepatocytes
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Figure 2: Close natural apposition of m-stellate cells and h-
hepatocytes in a chimeric liver. A serial section shown in Figure 1
was doubly stained with h-CK8/18 (green) for h-hepatocytes and
m-desmin (orange) for m-stellate cells. The h-hepatocytes are well
organized and closely apposed to m-stellate cells in Disse’s space.
Arrows indicate representative h-hepatocytes (green) and m-stellate
cells (orange). Bar, 10μm.
All six mRNAs were ampliﬁed to detectable levels, which
were higher in mice with higher RI values. Thus, the h-
hepatocytes in the chimeric mice appeared to express the six
h-CYP genes in a manner similar to their expression in the
h-body.
We then asked whether these normally expressed h-
CYPs in the h/m-chimeric liver were inducible in a drug-
speciﬁc manner. The h-CYP3A4 and h-CYP1A subfamilies
speciﬁcally respond to rifampicin and 3-methylcholanthrene
(3-MC),respectively[26].Chimericmicewithh-hepatocytes
were injected intraperitoneally with rifampicin or 3-MC,
once per day for 4 days. The mRNA levels of the six h-CYPs
in the liver tissues were measured 24 h after the last injection.
Rifampicin treatment enhanced the expression of h-CYP3A4
by 5.8-fold, but did not aﬀect the levels of the other ﬁve h-
CYPs. The administration of 3-MC enhanced CYP1A1 and
CYP1A2 mRNA levels by 10.0-fold and 6.4-fold, respectively,
but had no eﬀect on the other four CYPs. Neither rifampicin
nor 3-MC induced the expression of any of the six h-
CYPs in miceAlb-uPA/SCID that had not been transplanted
with h-hepatocytes. Rifabutin, an analogue of rifampicin,
also speciﬁcally induced h-CYP3A, but not the host murine
Cyp3a, in the chimeric m-liver [27]. The degree of CYP3A4
induction in the chimeric mouse has practical applications
in drug testing, because many drugs are CYP3A4 substrates
and the induction of CYP3A4 decreases the pharmacological
potency of these drugs [17].
Rifampicin is a ligand for the pregnane X receptor
(PXR), which forms a heterodimer with retinoid X receptor
a (RXRa). Rifampicin/PXR/RXRa subsequently binds to
a xenobiotic response element (XRE) composed of the
direct repeat of alpha and beta half-sites separated by
four nucleotides on the CYP3A4 gene, thereby upregulating
its expression in phase 1 [28]. Rifampicin is a potent
activator of human and rabbit PXR, but has little activity
in the rat and mouse [29]. Thus, that the liver data of
h/m-chimeric mice faithfully reﬂect those in humans. The
binding of 3-MC to the aryl hydrocarbon receptor (AHR)
forms a AHR/3-MC complex, which upregulates CYP1A1,
CYP1A2, and CYP1B1 expression by binding, together with
the AHR nuclear translocator (ARNT), to the XREs of
these genes [30]. Our studies suggest that these known
ligand-activated receptor signaling pathways activated by
rifampicin and 3-MC are functional in the h/m-chimeric
m-liver. Thus, we propose that the hepatocyte-humanized
mouse will be a useful animal model in studies of h-type
signaling pathways that regulate gene expression induced by
xenobiotics.
5. Humanization of Phase II Conjugation
Pathway of a Drug inh/m-ChimericMice
It is estimated that phase II conjugation accounts for
approximately >30% of drug clearance [31], especially of
compounds with polar groups. The major hepatic phase
II enzymes in humans are UDP-glucuronosyltransferase
(UGT), which is responsible for glucuronidation; sulfo-
transferase(SULT),forsulfation; N-acetyltransferase(NAT),
for acetylation; and glutathione S-transferase (GST), for
glutathione conjugation. We examined the mRNA and
protein expression and the enzyme activity of the h-forms of
these enzymes in chimeric mice with livers having RI values
ranging from 0 to 90% [32]. The chimeric livers expressed h-
UGT, h-SULT, h-NAT, and h-GST mRNA and the UGT2B7,
SULT1E1, SULT2A1, and GSTA1 proteins at levels that
correlated with their RI values. Activities of related enzymes
such as morphine 6-glucuronosyltransferase and estrone
3-sulfotransferase were also detected in an RI-dependent
manner. The protein content and enzyme activities of phase
II-associated enzymes in chimeric m-livers with an RI of
approximately 90% were similar to those in the donor liver.
In a separate study, we systematically compared the mRNA
expressionproﬁlesfor26phaseII h-enzymes,includingGST,
SUL, NAT, and UGT members, between livers of chimeric
mice with RIs of 71–89% and donor livers [16]. All of
the tested enzyme genes were detected. For 65% of the
tested genes, the expression levels in the chimeric livers
were 30 to 55% of the levels in the donor livers; although
lower, these values are comparable to the RI values. These
results indicate that the hepatic phase II biotransformation
of a drug is appreciably humanized in the h/m-chimeric
mouse.
There are groups of drugs in clinical use that bind
to PXRs or constitutive androstane receptors (CARs). The
ligand-activated PXRs and CARs are involved in the reg-
ulation of some phase II XME genes such as SULT1A,
UGT1A, and GST [33–35]. Thus, it is likely that these h-type
ligand-activated transcriptional regulators are functional in
h/m-chimeric m-livers, suggesting that these chimeric mice
will contribute to studies on the regulation of gene and
protein expression of these transcription factors in relation
to xenobiotic metabolism.6 PPAR Research
6. Drug Transport through the Chimeric
m-HepatocyteMembrane
Drug transport in the liver is largely performed by two sys-
tems: extrahepatic-to-hepatic transport using transporters
such as organic cation transporter 1 (OCT1), organic
anion transporting polypeptide (OATP) 1B1, and OATP1B3;
and hepatic-to-bile duct transport using adenosine 5 -
triphosphate-binding cassette (ABC) proteins, including P-
glycoprotein, bile salt export pump (BSEP/ABCB11), breast
cancer resistance protein (BCRP/ABCG2), and multidrug
resistance-associated protein 2 (MRP2) [36]. The former
transporters are located on the sinusoidal membrane and
are responsible for the uptake of drugs into hepatocytes; the
latter are on the canalicular membrane and are responsible
for biliary excretion of the metabolites. The h-genes of
these transporting systems were preferentially expressed
compared with the m-counterpart genes in chimeric mice
with RIs >60% [36]. Cefmetazole (CMZ), a cephalosporin
antibiotic, is excreted without any chemical modiﬁcation,
through urinary and biliary pathways. The urinary pathway
is dominant in humans [37], whereas rats [38]a n dm i c e
[36] use the biliary pathway. Before receiving h-hepatocytes,
the host mice excreted CMZ primarily through the biliary
pathway, but the urinary pathway was dominant in chimeric
mice with RIs >60% [36].
The h-ABCB4 transporters have been characterized
in relation to ﬁbrate-metabolism [39]. In addition, we
examined the expression levels of 21 h-transporter genes,
including members of the ABC, solute carrier (SLC), and
OATP families, in the livers of chimeric mice with RIs
ranging from 71 to 89%, with respect to the levels in donor
livers [16]. For 62% of the tested genes, the expression ratios
in the chimeric livers were 0.35 to 0.75. From these limited
data, it appears that most of the h-type transporter genes
were expressed in the chimeric m-liver.
7. Infectivityof Chimeric Mice with
h-HepatitisViruses
h-Liver diseases caused by HBV and HCV, especially HCV,
are targets for the discovery of eﬃcient antivirus drugs,
worldwide [40]. However, the development of eﬀective
therapeutics has been hampered by the lack of useful in vitro
andinvivomodelsofviralreplication.Forexample,cultured
h-hepatocytes are not appropriate as recipient cells for viral
propagation, and rodents are not useful animal models
because of the strict species speciﬁcity of viral infection
[41]. Viral infectivity and propagative potential in the h/m-
chimericmousewouldbepersuasiveevidenceforconcluding
that it was actually “humanized.” A research group led by
Knetemanﬁrstchallengedchimericmicewithaninoculation
of HCV-infected h-serum, which produced a virus-infected
model mouse [7]. Owing to their substantial advantage in
both magnitude and duration of h-hepatocyte engraftment,
homozygous animals were superior to their hemizygous
counterparts in this regard. Initial increases in total viral
load were up to 1950-fold, with replication conﬁrmed by the
detection ofnegative-strandviralRNAin transplantedlivers.
HCV viral proteins were localized to h-hepatocyte nodules,
and infection was serially passed through three generations
of mice, conﬁrming both synthesis and release of infectious
viralparticles.Usingh-hepatocyte-chimericRug-2-knockout
mice as test animals, Dandri et al. was the ﬁrst to succeed in
producing in vivo HBV infection [6].
We studied HBV infectivity in the chimeric mice [42].
After mice were inoculated with h-serum containing HBV, a
high level of viremia occurred in mice for up to 22 weeks.
Passage experiments showed that the serum of these mice
contained infectious HBV. As shown previously for HCV,
the level of HBV viremia tended to be high in mice with
a continuously high RI. Furthermore, lamivudine, an anti-
HBV drug, eﬀectively reduced the level of viremia in the
infected mice. Thus, the chimeric mouse may be an ideal
model in which we can develop and evaluate anti-h-hepatitis
virus drugs.
8. The h/m-Chimeric Mouseas anAnimal
Model for the Study of h-Type Peroxisome
Proliferator-ActivatedReceptors
8.1. Drug Metabolism under The Control of Ligand-Activated
Receptors. Biochemical systems in the liver manage not only
endogenous (homobiotic), but also xenobiotic molecules.
These molecules are ﬁrst recognized by speciﬁc protein
receptors on the hepatocyte surface. In general, the binding
of a ligand to its receptor generates a signal that ultimately
changesgeneexpression,producingacellularresponse.Hep-
atocytes possess four types of receptors [16], all of which are
ligand-activated transcriptional regulators: CAR; PXR [also
called steroid X receptor (SXR)]; peroxisome proliferator-
activated receptor (PPAR); and aryl hydrocarbon receptor
(AHR). The ﬁrst three belong to the nuclear receptor (NR)
superfamily, which consists of seven subfamilies, 1 to 6 and 0
[43]. AHR is a member of the Per-AhR/Arnt-Sim homology
sequence (PAS)/basic helix-loop-helix (HLH) superfamily,
which also represents the period regulator of circadian
rhythm (PER), Ah receptor nuclear translocator (ARNT),
and single-minded regulator of midline cell diﬀerentiation.
Historically, the roles of PPARs have been studied using
liver. They belong to NR subfamily 1, along with thyroid
hormonereceptor,retinoicacidreceptor(RAR),andvitamin
D receptor (VDR). As transcription factors, these receptors
share a similar process. They are activated by ligand binding;
form heterodimers, usually with the retinoid X receptor
(RXR); translocate to the nucleus; bind to a cis-acting
XRE consisting of a direct repeat of two hexanucleotides,
separated by one or two nucleotides, in the promoter region
of the target gene; and enhance target gene expression
[17]. Generally, in the absence of ligand, subfamily 1 NR
heterodimers are bound to co-repressor proteins and repress
transcription when bound to the cis-acting element [44].
Upon ligand binding, the receptor dissociates from the co-
repressors and associates with coactivator proteins, which
enables the NRs to promote gene expression.PPAR Research 7
Three PPAR subtypes are currently known [45]: PPARα
(or NR1C1),PPARβ/δ (NR1C2), and PPARγ (NR1C3).
When continuously exposed to certain xenobiotics such as
hypolipidemicdrugs,plasticizers,andherbicides,whichhave
little apparent structural relationship, rats and mice may
show hepatic peroxisome proliferation (increase in volume
and number) leading to hepatic tumors; this suggests a
correlation between the stimulation of genes for fatty acid β-
and ω-oxidation enzymes and the hepatic neoplastic process
[46, 47]. Reddy and Rao [48] proposed that speciﬁc soluble
binding sites for these drugs, collectively termed peroxisome
proliferators (PPs), were present in liver and kidney cell
extracts [49, 50]. The PPAR gene was ﬁrst cloned as a
member of the steroid hormone receptor superfamily from
a m-hepatic cDNA library [51]. This gene corresponds to
PPARα, according to the current nomenclature. Two years
later, three closely related members of the PPAR family
(xPPARα, β,a n dγ) were isolated from a Xenopus ovary
cDNA library and were shown to activate the promoter of
the acyl coenzyme A oxidase (ACO) gene, which encodes the
keyperoxisomalfattyacidβ-oxidationenzyme[52].xPPARα
is homologous to Issemann’s PPARα [51], and xPPARγ is
currently placed in the PPARγsubfamily, together with other
homologous members found in mammals. Mammalian
PPARδ w a si nan e wP P A Rg r o u pb e c a u s eo fad i ﬀerence
in amino acid sequence compared with xPPARβ;h o w e v e r ,
it is presently considered to be a PPARβ and is designated
as PPARβ/δ [45]. Of the three PPARs, PPARα is the most
critical in the present review, because it is expressed at high
levels in the liver, activates fatty acid catabolism, stimulates
gluconeogenesis and ketone body synthesis, and participates
in the control of lipoprotein assembly [45].
8.2. Species Diﬀerences in PPARα-Associated Signaling. The
PPARα isotype has prime importance for studies with
animal models to predict the eﬀects of hepatic PPs in
humans, because PPARα agonists induce seemingly quite
diﬀerent actions in rodents and humans [53]. Originally,
as the name indicates, PPARs were studied because of their
abilitytobindPPsandconsequentlyinducePP-metabolizing
enzymes. In rats and mice, but not in humans, PPs such as
hypolipidemic drugs, industrial plasticizers, and herbicides
are non-genotoxic carcinogens that cause liver tumors [54].
Inhumans,thesedrugsfunctiontomaintainlipidhomeosta-
sis and do not induce peroxisome proliferation. Thus, the
toxicity and carcinogenicity of PPs are highly species speciﬁc
[55]. The species diﬀerences may be attributable to lower
PPAR mRNA expression levels in h-hepatocytes compared
with rodent cells [56, 57]. Alternatively, or additionally,
species diﬀerences may be the result of diﬀerent sensitivities
of the genes associated with the peroxisome proliferation
response to low levels of PPs, owing to structural dif-
ferences in PPARα [54]. There are both similarities and
diﬀerences in responses to xenobiotics among not only
diﬀerent species (interspecies) but also individuals of the
same species (intraspecies). Interspeciﬁc PPARα diversity
between rodents and humans is well known and has been
studied with respect to drug metabolism. NR subfamily 1
members have at least two functions in mammals. One
is to regulate peroxisome proliferation through binding to
PPAR response elements (PPREs) in the promoters of genes
such as ACO [58, 59], bifunctional dehydrogenase/hydratase
(BFE) [60], and microsomal CYP4A1 [61]. The other
is to modulate the serum cholesterol level by targeting
genes such as the lipoprotein lipase gene [62] and the
apolipoprotein regulating genes AI, AII, and CII [63]. The
formermechanismappearstofunctioninrodents,butnotin
humans, and is responsible for the induction of peroxisome
proliferation and hepatocarcinogenesis, whereas the latter
mechanism controls basic lipid metabolism in both rodents
and humans [56]. This species diﬀerence in xenobiotic
receptor/ligand signaling may be attributable to diﬀerences
in the expression level of a receptor, or to diﬀerences in
receptor/ligand binding aﬃnity, and causes diﬃculty in
determining responses in humans based on rodent data [56].
8.3. PPARα Gene-Humanized Mice. One approach to over-
coming species diﬀerences is to generate “humanized”
transgenic mice (gene-humanized mice), in which a h-
gene of interest is introduced into the m-genome [17]. A
PPARα gene-humanized m-line that expresses the h-PPARα
gene [64] under the control of the tetracycline responsive
regulatory system in the liver of murine PPARα gene-
null mice [65] has been created. These mice functionally
responded to the expected ligands as wild-type mice, but
did not exhibit the hepatocellular proliferation, including
increases in peroxisomes, seen in wild-type mice. Thus, this
approach may help overcome species diﬀerences and provide
animalmodelssuitableforstudyingh-responsesregulatedby
genes of interest.
8.4. PPAR Signaling in Chimeric Mice. Considering the
prominent roles and the species divergence of PPARs in the
response to xenobiotics, it is important to study h-PPAR-
related responses of the h/m-chimeric mouse. We examined
the eﬀects of ﬁbrates (antihyperlipidemic drugs and PPAR
agonists) [63, 66] in the chimeric mice. Given the central
role of the liver in PPAR-regulated lipid metabolism and the
use of ﬁbrate compounds in a variety of clinical drugs, the
responses of h/m-chimeric mice to ﬁbrates and PPARs may
have important practical implications.
Hepatocytes secrete biliary phospholipids, composed
largely of phosphatidylcholine (PC), through multidrug-
resistance2P-glycoprotein(MDR3,orABCB4)embeddedin
the canalicular membrane. MDR3 was shown to translocate
PC in a study using mdr2 gene (a murine homolog
of h-MDR3) knockout mice. These mice completely lack
phospholipids in their bile [67], but the bile PC is fully
recovered with the overexpression of h-MDR3 [68]. The
expression level of the h-MDR3 gene aﬀects the development
of hepatobiliary diseases [69].
Fibrates upregulate mdr2 gene expression [70], which is
associated with an increase in biliary phospholipid secretion
[71]. Benzaﬁbrate (BF), a second-generation ﬁbrate analog,
wasclinicallyshowntoreduceelevatedserumbiliaryenzyme
levels in patients with chronic cholestatic liver disease8 PPAR Research
[72]. It was shown to bind to PPARβ/δ and α,w i t ha
higher aﬃnity for the former, and was thus said to be a
bona ﬁde PPAR ligand [73]. Other researchers created a
coactivator-dependent receptor-ligand in vitro interaction
assay and demonstrated that BF was a ligand for PPARα,
β/δ,a n dγ [74]. The same researchers also showed drug-
induced activation of PPARα/RXRα,P P A R β/δ/RXRα,a n d
PPARγ/RXRα [74].
BF induces an increase in ABCB4 (MDR3), and its
redistribution in the cell membrane. This induction was
associated with an enhanced capacity of h-hepatocytes to
direct PC into bile canaliculi [75]. Furthermore, ABCB4
redistribution was attenuated when PPARα expression was
suppressed by small interfering RNA or morpholino anti-
sense oligonucleotides in cultured HepG2 cells (hepato-
blastoma cells) [75], strongly suggesting the necessity for
PPARα in the BF-induced activation of PC secretion in h-
hepatocytes.
We tested the ability of the h/m-chimeric m-liver to
exhibit h-type PPAR-dependent responses by administering
BF to the chimeric mice. Mice with RIs of 60–80% were
fed a standard laboratory chow containing 0.3% (wt/wt)
BF for 7 days, and their livers were analyzed for MDR3
mRNA and protein expression [39]. The mRNA level in the
BF-treated mice was approximately 2-fold the level in non-
treated control mice. The protein level was approximately
3.5-fold that in the controls. The ﬁbrate induced a robust
redistribution (exocytosis and insertion) of MDR3 proteins
into the bile canaliculi.
Although studies on the expression and function of
PPARs in the h/m-chimeric m-liver are limited, we conclude,
based on the studies described above, that the chimeric
m-liver exhibits the phenotypes of PPAR-regulated physi-
ological and pathological processes, including responses to
xenobiotics, that are normally present in the h-liver in vivo.
9.SummaryandProspective
After administration, a xenobiotic is generally and largely
absorbed by the liver, intracellularly distributed, metab-
olized, and secreted through the bile or urinary ducts.
These steps, collectively termed absorption, distribution,
metabolism,andexcretion(ADME),areinterdependent,and
drug pharmacokinetics are determined by the parameters
resulting from these interactive processes. There are marked
species diﬀerences in the many genes and proteins associated
withADMEofaxenobiotic.Thediﬀerencesbetweenhumans
androdentsdictatethatpharmacokineticdatadetermined in
rodents must be very cautiously, deliberately, and correctly
extrapolated to humans in order to ensure that the drug will
be safe and eﬀective in patients. Until recently, h-hepatocyte-
chimeric mice have been studied primarily in relation to
CYP-associated metabolism, representing the M of ADME,
and HCV/HBV infection. These studies have shown that the
chimeric mice are signiﬁcantly and appreciably humanized,
providing a reliable and promising animal model for pre-
dicting drug metabolism and eﬃcacy in humans. Although
data have also been accumulated for the A, D, and E
steps of ADME, more work is required before reaching an
appropriate conclusion concerning the humanization of a
chimericmousewithrespecttotheseprocesses.Nevertheless,
currently available data appear to demonstrate that these
processes are also well humanized.
Based on our studies and experiences to date, the h-
hepatocyte-chimeric mice exhibit h-type liver responses at
thegeneandproteinlevels.Thesemicecanmimicthesteady-
state expression in the h-liver in the absence of exogenous
stimuli and exhibit the expected h-type responses upon
stimulation. However, we must consider the limitations of
chimeric mice. Current chimeric mice carry hepatocytes
only of human origin, but all other cells are of m-origin.
To perform liver functions, parenchymal cells require non-
parenchymal cells, which are of mouse, and not of human,
origin in the chimeric mice. Some interactions between h-
hepatocytes and m-nonparenchymal cells may proceed as
normal homogeneous interactions, and some may not.
In addition, endocrinological regulation is crucial for
hepatocytes to achieve normal metabolic homeostasis and to
return to normal conditions after endogenous or exogenous
factors have caused metabolic parameters to extend beyond
the normal range. Chimeric livers are under the inﬂuence
of the m-endocrinological system, and some m-hormones
such as growth hormone (GH) are not able to act on h-
cells, because a hormone-receptor complex does not form
between m-GH and h-hepatocyte receptors [76]. In support
of this notion, h-hepatocytes administered with h-GH
showed enhanced expression of liver growth-associated h-
genes, including IGF-1, STAT-3, Cdc 25A, and cyclinD1, and
repopulated the host liver at a rate approximately 6-fold that
inthecontrol.Despitethesepossiblelimitations,weconsider
the chimeric mouse to be the best animal model to date
for h-liver function studies, because the chimeric mice with
high RI values not only expressed h-liver proteins but also
mimicked h-liver functions. Five years ago, we started mass
production of homogenous populations of the hepatocyte-
humanized mice with high RIs to facilitate research activities
in the academic and industrial communities, including
examinations of h-type metabolism of new drugs for h-use,
the study of h-HCV infection mechanism and propagation,
and the development of new anti-HCV-drugs. However, we
are still in the initial stages of characterizing various aspects
of the chimeric mice. Further study will systematically
reveal the advantages and limits of this newly developed
hepatocyte-humanized mouse.
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